# Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

> **NCT01339663** · PHASE1 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** autologous tumor cell vaccine
- **OTHER:** laboratory biomarker analysis
- **OTHER:** immunologic technique
- **OTHER:** immunohistochemistry staining method
- **GENETIC:** polymerase chain reaction
- **BIOLOGICAL:** therapeutic autologous lymphocytes

## Key facts

- **NCT ID:** NCT01339663
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-12
- **Final completion:** —
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01339663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01339663, "Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01339663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*